ArticleInternational journal of nanomedicine2025
Platelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) Nanoparticles as a Targeting Drug Delivery System for Multidrug-Resistant Breast Cancer.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management.Drug delivery and translational research · 2026Article
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Platelet membrane-coated nanoparticles: Bioengineering principles, quality control, and translational opportunities.APL bioengineering · 2026Review
- Biomimetic hybrid membrane-coated nanoparticles loaded with rhein-iron complex enhance ferroptosis and immunotherapy for triple-negative breast cancer.Materials today. Bio · 2026Article
- Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation.Experimental hematology & oncology · 2026Review
- Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies.Drug design, development and therapy · 2026Review
- In Vivo Behavior of Biomimetic Nanoparticles: Strategies for Clearance Avoidance, Targeting, and Functional Delivery.Molecules (Basel, Switzerland) · 2025Review
- Integrative genomic analysis reveals causal relationships between breast mammary tissue gene expression and breast cancer risk using multi-method Mendelian randomization.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Paclitaxel (PTX), widely used chemotherapeutic agent, is limited by poor solubility, P-glycoprotein (P-gp) mediated efflux, and non-specific toxicity. To overcome these challenges, we developed a triple-functionalized nanocarrier system incorporating poly(lactide-co-glycolide) (PLGA)-based nanoparticles (PNs), D-α-tocopheryl polyethylene glycol succinate (TPGS) for P-gp inhibition, and platelet membrane (PM) coating for targeted tumor delivery. Methods: The PM-coated TPGS-modified PNs with PTX (PTPNs) was characterized by particle size analysis, transmission electron microscopy (TEM), and protein assay to confirm PM coating. In vitro drug release studies were conducted under acidic conditions mimicking the tumor microenvironment. Cellular assays were performed to evaluate cytotoxicity and drug efficacy in multidrug-resistant MCF-7/ADR cells. In vivo biodistribution and xenograft studies assessed tumor accumulation and therapeutic outcomes. Results: PTPNs exhibited a particle size of 221 ± 2 nm with a PDI of 0.090 ± 0.020 and a zeta potential of -30.5 ± 0.3 mV, indicating a homogeneous particle distribution and successful PM coating. The optimal PM-to-PLGA weight ratio was determined to be 0.005, which ensured structural stability and uniform coating in physiological conditions. Sustained PTX release was observed in acidic conditions, mimicking the tumor microenvironment. Cellular assays showed a 17-fold reduction in PTX IC Conclusion: The PTPNs enhanced PTX delivery by improving tumor specificity, overcoming multidrug resistance, and reducing systemic toxicity. These results suggested the potential of this biomimetic approach to advance cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.